• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Cellectar Biosciences Inc.

    7/2/25 12:15:15 AM ET
    $CLRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLRB alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: July 1, 2025 9:00 A.M.
    Form: S-1
    CIK: 0001279704
    Company Name: Cellectar Biosciences, Inc.
    File Number: 333-288333
    Get the next $CLRB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLRB

    DatePrice TargetRatingAnalyst
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $CLRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:02:08 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:01:18 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:00:13 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

      Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

      12/5/24 8:32:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:02:08 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:01:18 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:00:13 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

      FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the "Company"), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds and executive management. The offering is composed of (i) 1,045,000 Class A Units (which includes 180,000 Class A Units issued pursuant to the Underwriter's exercise of the over-allotmen

      7/2/25 4:15:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

      FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the "Company"), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 865,000 Class A Units with each Class A Unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the "Common Warrants"), and (ii) 335,000 Class B Units with each Class B Unit consisting of

      7/1/25 9:25:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $CLRB
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cellectar Biosciences Inc.

      EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)

      7/2/25 12:15:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Cellectar Biosciences Inc.

      424B4 - Cellectar Biosciences, Inc. (0001279704) (Filer)

      7/1/25 7:45:51 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.

      S-1/A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      6/30/25 8:29:31 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

      William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

      10/17/23 8:00:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

      ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Douglas J. Swirsky has been appointed as the Company's Chief Financial Officer, effective immediately. Mr. Swirsky is a seasoned financial leader with over two decades of experience in the healthcare sector, including as a public company executive at Nasdaq-listed organizations. "We are excited to welcome Douglas to MaxCyte where he brings exceptio

      3/27/23 4:05:00 PM ET
      $CLRB
      $MXCT
      $REXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Major Pharmaceuticals

    $CLRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 4:47:59 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 1:26:20 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      8/14/24 7:15:55 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    Financials

    Live finance-specific insights

    See more
    • Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clini

      5/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care